FindTrial
Sign In

Discovery of biomarkers in the diagnosis and treatment of benign prostate hyperplasia

Discovery of biomarkers in the diagnosis and treatment of benign prostate hyperplasia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020339
Enrollment
Unknown
Registered
2018-12-25
Start date
2018-12-31
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostate hyperplasia

Interventions

Gold Standard:Histology diagnosis
Index test:Changes&#32
in&#32
sex&#32
hormones&#32
and&#32
their&#32
metabolite&#32
levels.

Sponsors

The affiliated hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Disease group: Men with benign prostatic hyperplasia. Healthy control group: Age matched healthy men with the disease group, with no history of prostate hyperplasia and self-reported health.

Exclusion criteria

Exclusion criteria: Suffering from other urological diseases; those who have undergone prostatectomy; those with metabolic related diseases; those who have taken treatment for hyperplasia; the history of substance abuse such as tobacco and alcohol; the type 2 diabetes diagnosed ;with severe hypertension.

Design outcomes

Primary

MeasureTime frame
DHEA, A4, T, DHT, A, E2, E1;SEN;SPE;ACC;—

Countries

China

Contacts

Public ContactXiaoxin Yin Junjie Liu

Xuzhou Medical University

yinxx@xzhmu.edu.cn+86 13605218523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026